Helmuth van Es


Helmuth a co-founder of Antabio, was part of the founding team of Galapagos, now a clinical stage development company, in 1998. As Head of Science, he established multimillion dollar alliances with GSK, Incyte, Pharmacia, CF foundation and others. Since Galapagos Helmuth founded BioConsilium and co-founded drug-discovery companies Audion Therapeutics (2008 based on Harvard IP) targeting hearing loss, Eli Lilly and INKEF Capital are current investors; Effecta Pharma focussing on novel antivirals (2009) (in particular flavivirus); Citryll a single asset company focussing on a first in class NET inhibiting therapeutic antibody targeting SLE, vasculitis, RA and other autoimmune diseases.